申请人:BEECHAM GROUP PLC
公开号:EP0139296A2
公开(公告)日:1985-05-02
A compound of formula (I) or a pharmaceutically acceptable salt thereof:
wherein:
R1 and R2 are independently hydrogen, C1-6 alkyl or together are a group X which is C3-6 polymethylene optionally interrupted by 0, S or NR6 wherein R6 is hydrogen or C1-6 alkyl;
R3 is phenyl, optionally substituted by one or more substituents selected from halogen, CF3, nitro, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C2-7 alkanoyl, carboxyl, C1-6 alkoxycarbonyl, cyano, CONR7R8 wherein R7 and Rs are selected from hydrogen or C1-6 alkyl or together are a group X;NR9R10 wherein R9 and R10 are selected from hydrogen, C1-6 alkyl, C2-7 alkanoyl or C1-6 alkylsulphonyl or together are a group X; SO2NR11R12 wherein R11 and R12 are selected from hydrogen or C1-6alkyl or together are a group X or S(O)mR13 wherein m is 1 or 2 and R13 is C1-6 alkyl; R4 and Rs are independently selected from hydrogen, C1-6 alkyl, cyano, amino, aminocarbonyl or aminocarbamoyl optionally substituted by one or two C1-6 alkyl groups ortogether are a group X, halogen, CF3, nitro, C1-6 alkoxy, C1-6 alkylthio, C2-7 alkanoyloxy, C1-6 alkoxy or hydroxy, or together are methylenedioxy or C3-5 polymethylene, having anti-inflammatory and/or anti-rheumatic activity, a process for their preparation and their use as pharmaceuticals.
式 (I) 的化合物或其药学上可接受的盐:
其中
R1 和 R2 独立地为氢、C1-6 烷基或共同为基团 X,该基团 X 为任选被 0、S 或 NR6 中断的 C3-6 聚亚甲基,其中 R6 为氢或 C1-6 烷基;
R3 是苯基,可任选被一个或多个取代基取代,这些取代基选自卤素、CF3、硝基、C1-6 烷基、C1-6 烷氧基、C1-6 烷硫基、C2-7 烷酰基、羧基、C1-6 烷氧羰基、氰基、CONR7R8,其中 R7 和 Rs 选自氢或 C1-6 烷基,或共同组成基团 X;NR9R10,其中 R9 和 R10 选自氢、C1-6 烷基、C2-7 烷酰基或 C1-6 烷基磺酰基,或二者为一个基团 X; SO2NR11R12,其中 R11 和 R12 选自氢或 C1-6 烷基,或二者为一个基团 X 或 S(O)mR13,其中 m 为 1 或 2,R13 为 C1-6 烷基;R4和Rs独立地选自氢、C1-6烷基、氰基、氨基、氨基甲酰基或氨基甲酰基,可任选被一个或两个C1-6烷基取代,或共同为基团X、卤素、CF3、硝基、C1-6烷氧基、C1-6烷硫基、C2-7烷酰氧基、C1-6烷氧基或羟基,或共同为亚甲基二氧基或C3-5聚亚甲基,具有抗炎和/或抗风湿活性,其制备方法和作为药物的用途。